HUE043194T2 - PLK-4 inhibitor sója és kristályformái - Google Patents

PLK-4 inhibitor sója és kristályformái

Info

Publication number
HUE043194T2
HUE043194T2 HUE14854037A HUE14854037A HUE043194T2 HU E043194 T2 HUE043194 T2 HU E043194T2 HU E14854037 A HUE14854037 A HU E14854037A HU E14854037 A HUE14854037 A HU E14854037A HU E043194 T2 HUE043194 T2 HU E043194T2
Authority
HU
Hungary
Prior art keywords
plk
inhibitor
salt
crystalline forms
crystalline
Prior art date
Application number
HUE14854037A
Other languages
English (en)
Hungarian (hu)
Inventor
Peter Brent Sampson
Miklos Feher
Heinz W Pauls
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of HUE043194T2 publication Critical patent/HUE043194T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14854037A 2013-10-18 2014-10-17 PLK-4 inhibitor sója és kristályformái HUE043194T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361892564P 2013-10-18 2013-10-18

Publications (1)

Publication Number Publication Date
HUE043194T2 true HUE043194T2 (hu) 2019-08-28

Family

ID=52827507

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14854037A HUE043194T2 (hu) 2013-10-18 2014-10-17 PLK-4 inhibitor sója és kristályformái

Country Status (27)

Country Link
US (5) US9884855B2 (enExample)
EP (1) EP3057965B1 (enExample)
JP (1) JP6492072B2 (enExample)
KR (3) KR20220063299A (enExample)
CN (2) CN105764899B (enExample)
AU (1) AU2014336929B9 (enExample)
CA (1) CA2926845C (enExample)
CY (1) CY1121484T1 (enExample)
DK (1) DK3057965T3 (enExample)
EA (1) EA031569B1 (enExample)
ES (1) ES2718603T3 (enExample)
HR (1) HRP20190564T1 (enExample)
HU (1) HUE043194T2 (enExample)
IL (1) IL245038B (enExample)
LT (1) LT3057965T (enExample)
ME (1) ME03377B (enExample)
MX (1) MX359069B (enExample)
NZ (1) NZ718744A (enExample)
PL (1) PL3057965T3 (enExample)
PT (1) PT3057965T (enExample)
RS (1) RS58413B1 (enExample)
SG (1) SG11201602783SA (enExample)
SI (1) SI3057965T1 (enExample)
SM (1) SMT201900124T1 (enExample)
TR (1) TR201902875T4 (enExample)
TW (1) TWI659952B (enExample)
WO (1) WO2015054793A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5629752B2 (ja) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークUniversity Health Network キナーゼインヒビターおよびこれを用いた癌の治療方法
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
CN105764899B (zh) 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
AU2018328773B2 (en) * 2017-09-08 2023-11-16 University Health Network Combination therapies for inhibition of Polo-like Kinase 4
BR112021021106A2 (pt) 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
JP2023505301A (ja) * 2019-12-06 2023-02-08 ユニバーシティー ヘルス ネットワーク 急性骨髄性白血病または骨髄異形成症候群に対する治療
AU2022272184A1 (en) 2021-05-11 2023-11-30 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483323A (en) * 1945-08-01 1949-09-27 Kay Fries Chemicals Inc Method of preparing phenyl ethyl alcohol
AU2003286604A1 (en) 2002-10-21 2004-05-13 Irm Llc Oxindoles with anti-hiv activity
DE102005005395A1 (de) 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
WO2008118097A1 (en) * 2007-03-23 2008-10-02 Agency For Science, Technology And Research Palladium catalysts
WO2009042711A1 (en) * 2007-09-25 2009-04-02 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
CA2709536C (en) * 2007-12-21 2016-05-31 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
JP5629752B2 (ja) * 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークUniversity Health Network キナーゼインヒビターおよびこれを用いた癌の治療方法
CN102428086B (zh) 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
SI2556071T1 (sl) * 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
US8933070B2 (en) 2010-07-02 2015-01-13 University Health Network Methods of targeting PTEN mutant diseases and compositions therefor
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EA024026B1 (ru) * 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
US9580390B2 (en) * 2011-10-12 2017-02-28 University Health Network Indazole compounds as kinase inhibitors and method of treating cancer with same
CN105764899B (zh) 2013-10-18 2021-06-01 大学健康网络 Plk-4抑制剂的盐和晶型
WO2015054781A1 (en) 2013-10-18 2015-04-23 University Health Network Treatment for pancreatic cancer

Also Published As

Publication number Publication date
AU2014336929B9 (en) 2019-03-21
EA031569B1 (ru) 2019-01-31
US10392374B2 (en) 2019-08-27
IL245038A0 (en) 2016-05-31
AU2014336929B2 (en) 2018-11-22
SMT201900124T1 (it) 2019-05-10
US10919886B2 (en) 2021-02-16
SG11201602783SA (en) 2016-05-30
PT3057965T (pt) 2019-04-23
SI3057965T1 (sl) 2019-04-30
CN113248486A (zh) 2021-08-13
TR201902875T4 (tr) 2019-03-21
JP6492072B2 (ja) 2019-03-27
TWI659952B (zh) 2019-05-21
US11667627B2 (en) 2023-06-06
EP3057965A4 (en) 2017-05-24
ES2718603T3 (es) 2019-07-03
IL245038B (en) 2019-11-28
US20180155335A1 (en) 2018-06-07
RS58413B1 (sr) 2019-04-30
PL3057965T3 (pl) 2019-08-30
KR20160070106A (ko) 2016-06-17
US9884855B2 (en) 2018-02-06
KR20210137251A (ko) 2021-11-17
MX2016004963A (es) 2016-06-28
CA2926845C (en) 2023-06-13
JP2016537326A (ja) 2016-12-01
NZ718744A (en) 2021-07-30
US20190248775A1 (en) 2019-08-15
EP3057965B1 (en) 2019-01-02
CN105764899A (zh) 2016-07-13
DK3057965T3 (en) 2019-04-01
MX359069B (es) 2018-09-12
US10472353B2 (en) 2019-11-12
US20160264559A1 (en) 2016-09-15
EP3057965A1 (en) 2016-08-24
CA2926845A1 (en) 2015-04-23
CY1121484T1 (el) 2020-05-29
KR102395737B1 (ko) 2022-05-10
KR20220063299A (ko) 2022-05-17
HRP20190564T1 (hr) 2019-05-17
ME03377B (me) 2020-01-20
CN105764899B (zh) 2021-06-01
TW201609717A (zh) 2016-03-16
US20210269428A1 (en) 2021-09-02
US20200140428A1 (en) 2020-05-07
WO2015054793A1 (en) 2015-04-23
EA201690755A1 (ru) 2016-09-30
LT3057965T (lt) 2019-03-12

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and uses thereof
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
HUE040434T2 (hu) Szelektív CDK4/6 inhibitor szilárd alakjai
IL240967A0 (en) Inhibitors of the kynurenine pathway
SMT201700363T1 (it) Inibitori di bromodominio cristallini
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT3057586T (lt) Bromodomeno inhibitoriai
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
DK3043785T3 (da) Anvendelse af r-ketamin og salt deraf som lægemidler
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
HUE042466T2 (hu) Eljárás és köztitermékek JAK inhibitor elõállítására
HUE046285T2 (hu) Omecamtiv mecarbil sói és eljárás a só elõállítására
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HUE053047T2 (hu) MDM2 inhibitor kristályos formája
SI3293176T1 (sl) Kristalna oblika inhibitorja PDE4
DK2958926T3 (da) Epidithiodioxopiperazinforbindelse eller derivater deraf og anvendelse deraf
EP3071554A4 (en) Crystalline forms of lesinurad and its sodium salt
HUE043194T2 (hu) PLK-4 inhibitor sója és kristályformái
DK3066089T3 (da) Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HUE056048T2 (hu) Helyettesített pirimidin vegyületek és SYK inhibitorként való alkalmazásuk
TH1401007310A (th) เอไมด์ของสารประกอบ 2-อะมิโน-4-เอริลไธอะโซลและเกลือของสารประกอบดังกล่าว
TH1501001781A (th) สารประกอบเตตระโซลิโนน และการใช้ของสิ่งนั้น
TH1501001044A (th) เกลือแอมีน และผลึกของสารนั้น
UA28690S (uk) Ендопротез голівки променевої кістки